Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and East
Get Alerts OREX Hot Sheet
Join SI Premium – FREE
SAN DIEGO, March 15, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) will host a conference call this afternoon to discuss the strategic acquisition of all U.S. rights to Contrave® and the Mysimba® commercialization and distribution agreement with Valeant Pharmaceuticals International, Inc. for Central and Eastern Europe.
The call will be held today at 8:30 a.m. ET / 5:30 a.m. PT and may be accessed by phone by calling (888) 771-4371 (domestic) or (847) 585-4405 (international), participant code 42093506. The webcast can be accessed live on the Investors section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.
Orexigen Contact: |
Media Contact: |
McDavid Stilwell |
Julie Normart |
VP, Corporate Communications and Business Development |
BrewLife |
(858) 875-8629 |
(415) 946-1087 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orexigen-therapeutics-to-host-conference-call-at-830-am-eastern-time-today-to-discuss-acquisition-of-us-rights-to-contrave-naltrexone-hcl--bupropion-hcl-extended-release-and-central-and-eastern-europe-distribution-agreeme-300236043.html
SOURCE Orexigen Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Marie Brizard Wine & Spirits: Q1 2024 revenues
- River City Bank Reports 2024 First Quarter Net Income of $18.7 Million and a Quarterly Cash Dividend
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!